Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744707 | 0.89 | THRA (0.58) | KEAP1NFE2L2FFAR4SLC22A12THRA | |
| SCHEMBL2350834 | 0.88 | SLC22A12 (0.44) | KEAP1NFE2L2FFAR4SLC22A12FFAR1 | |
| SCHEMBL16047970 | 0.75 | FFAR4 (0.46) | FFAR4FFAR1THRATHRB | |
| SCHEMBL16049180 | 0.74 | FFAR4 (0.67) | FFAR4FFAR1 | |
| SCHEMBL1520041 | 0.71 | KEAP1 (1.00) | KEAP1NFE2L2FFAR4SLC22A12CYP2A6 | |
| SCHEMBL31673864 | 0.71 | MAPT (0.63) | KEAP1NFE2L2FFAR4SLC22A12CYP2A6 | |
| SCHEMBL31673843 | 0.71 | MAPT (0.63) | KEAP1NFE2L2FFAR4SLC22A12CYP2A6 | |
| Hydrochloric Acid SCHEMBL6821885 | 0.70 | KEAP1 (0.97) | KEAP1NFE2L2FFAR4SLC22A12CYP2A6 | |
| SCHEMBL20985863 | 0.70 | THRA (0.45) | FFAR4FFAR1THRATHRB | |
| SCHEMBL16049132 | 0.70 | FFAR4 (0.69) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | KEAP1 3047/4885NFE2L2 2450/4885FFAR4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.